
GLP-TRZ
COA published
A dual GIP/GLP-1 receptor agonist peptide studied in comparative receptor-affinity research.

Metabolic
A synthetic triple receptor agonist peptide studied in in-vitro GIP, GLP-1 and glucagon receptor binding research.
Select size
Quantity
Total
$79.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificates of Analysis: 20266101 · FD-2606040289Headline purity is the lowest of these results.
Have a question?
For research use only. Not for human consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
Retatrutide (development code LY3437943) is a synthetic single-chain peptide engineered to engage three receptors at once — GIP, GLP-1 and glucagon. It is the third generation of a design lineage that began with single GLP-1 receptor agonists and moved through dual GIP/GLP-1 agonists: each step adds a receptor to the same peptide backbone. The engineering problem is balancing potency across three receptors in one molecule.
Characterised as a triple agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor — all three class-B G-protein-coupled receptors. The receptor-level literature cited below covers the structural biology of these targets: the cryo-EM structure of the activated GLP-1 receptor in complex with a G protein, and a review of GIP and its receptor. We describe this compound by its receptor targets and structure only. Not FDA-approved; supplied for laboratory research use only.
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.
Batch releases & restocks
Every certificate is published and available for review. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.

COA published
A dual GIP/GLP-1 receptor agonist peptide studied in comparative receptor-affinity research.

COA published
A small-molecule NNMT inhibitor studied in enzyme-inhibition and cellular-metabolism research models.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.